Published in Curr Opin Pharmacol on April 04, 2012
High expression of inositol polyphosphate phosphatase-like 1 associates with unfavorable survival in hepatocellular carcinoma. Int J Clin Exp Pathol (2013) 0.93
Inhibition of serum- and glucocorticoid-inducible kinase 1 enhances TLR-mediated inflammation and promotes endotoxin-driven organ failure. FASEB J (2015) 0.82
Sparse Modeling Reveals miRNA Signatures for Diagnostics of Inflammatory Bowel Disease. PLoS One (2015) 0.81
Phosphatidylinositol-3,4,5-triphosphate and cellular signaling: implications for obesity and diabetes. Cell Physiol Biochem (2015) 0.80
Molecular control of PtdIns(3,4,5)P3 signaling in neutrophils. EMBO Rep (2015) 0.79
Extract of Perilla frutescens inhibits tumor proliferation of HCC via PI3K/AKT signal pathway. Afr J Tradit Complement Altern Med (2012) 0.79
Detection and manipulation of phosphoinositides. Biochim Biophys Acta (2014) 0.79
Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5'-phosphatase (SHIP). Bioorg Med Chem Lett (2015) 0.75
All Trans Retinoic Acid, Transforming Growth Factor β and Prostaglandin E2 in Mouse Plasma Synergize with Basophil-Secreted Interleukin-4 to M2 Polarize Murine Macrophages. PLoS One (2016) 0.75
Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology (2004) 1.54
Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J Immunol (2002) 1.46
Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer. Int J Cancer (2008) 1.39
Phosphatidylinositol 3-kinase mediates activation of ATM by high NaCl and by ionizing radiation: Role in osmoprotective transcriptional regulation. Proc Natl Acad Sci U S A (2006) 1.28
The PI3K inhibitor arsenal: choose your weapon! Trends Biochem Sci (2007) 1.26
Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology (2002) 1.25
Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes. J Biol Chem (2007) 1.12
Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation. Trends Immunol (2007) 1.09
Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. Bioorg Med Chem Lett (2010) 1.04
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev (2012) 1.03
The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol (2005) 1.01
Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis. J Immunol (2004) 0.99
How does inflammation cause Barrett's metaplasia? Curr Opin Pharmacol (2009) 0.96
Optimal chemotactic responses of leukemic T cells to stromal cell-derived factor-1 requires the activation of both class IA and IB phosphoinositide 3-kinases. J Immunol (2003) 0.92
Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int Immunopharmacol (2006) 0.91
Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes. Immunology (2011) 0.90
Evidence that phospholipase-C-dependent, calcium-independent mechanisms are required for directional migration of T-lymphocytes in response to the CCR4 ligands CCL17 and CCL22. J Leukoc Biol (2006) 0.89
Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1. Org Biomol Chem (2011) 0.88
PI3Kgamma is the dominant isoform involved in migratory responses of human T lymphocytes: effects of ex vivo maintenance and limitations of non-viral delivery of siRNA. Cell Signal (2007) 0.88
Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology (2007) 0.88
Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists. J Leukoc Biol (2008) 0.85
Protein arginine methylation: a new handle on T lymphocytes? Trends Immunol (2010) 0.84
PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies. Curr Opin Investig Drugs (2009) 0.83
Evidence that the lipid phosphatase SHIP-1 regulates T lymphocyte morphology and motility. J Immunol (2011) 0.83
Cdx genes, inflammation and the pathogenesis of Barrett's metaplasia. Trends Mol Med (2009) 0.83
Development and characterisation of tetracycline-regulated phosphoinositide 3-kinase mutants: assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling. J Immunol Methods (2003) 0.83
Heterologous regulation of chemokine receptor signaling by the lipid phosphatase SHIP in lymphocytes. Cell Signal (2005) 0.82
Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities. Front Immunol (2012) 0.82
Leukocyte navigation mechanisms as targets in airway diseases. Drug Discov Today (2006) 0.81
Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP-1. Biochim Biophys Acta (2009) 0.80
Toll-like receptors in the spotlight. Nat Immunol (2003) 0.79
Genetic ablation of PI3Kγ results in defective IL-17RA signalling in T lymphocytes and increased IL-17 levels. Eur J Immunol (2012) 0.78
Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity. Anticancer Drugs (2008) 0.78
Evidence for PI3K-dependent CXCR3 agonist-induced degranulation of human cord blood-derived mast cells. Mol Immunol (2010) 0.78
New insights into mechanisms of gastrointestinal inflammation and cancer. Curr Opin Pharmacol (2009) 0.78
Assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling: use of dominant negative mutants controlled by a tetracycline-regulated gene expression system. Methods Mol Biol (2004) 0.76
Cell penetrating peptides fail to induce an innate immune response in epithelial cells in vitro: implications for continued therapeutic use. Eur J Pharm Biopharm (2013) 0.76
Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. Br J Pharmacol (2004) 0.76
Mitochondrial superoxide generation enhances P2X7R-mediated loss of cell surface CD62L on naive human CD4+ T lymphocytes. J Immunol (2013) 0.76
PI3K comes of age. Nat Immunol (2003) 0.75
Determination of nickel species in stack emissions from eight residual oil-fired utility steam-generating units. Environ Sci Technol (2011) 0.75
Spurs in the hunt for new immunomodulatory drug targets. Curr Opin Pharmacol (2012) 0.75